Biocom Venture Days are designed to connect member companies to Venture Capitalists from around the US.
Each event, organized by the Biocom Capital Development Committee, will feature a small group of VCs that come to San Diego for a day of 1:1 meetings with select companies. Companies will be selected by the VCs based on their investment criteria and scheduled 45 minute meetings/presentations with the VCs and company executives.
Interested in the latest developments in the venture capital market? Looking to raise money? Join us for our first Biocom Venture Day in Los Angeles with Rajeev Dadoo, Partner, SR-one, for a series of one-on-one meetings with pre-selected companies.
Looking at the past year, the venture capital ecosystem deployed $58.6 billion across the United States, which marks the second highest full year total in the last 20 years.* The biotechnology industry alone received the second largest amount of venture capital for Q3 2016 (after Software), with $1.8 billion going into 87 deals. That’s why Biocom is pleased to be your partner in accelerating the life science innovation ecosystem through Biocom Venture Days.
Our track record in 2016 includes over 125 one-on-one meetings arranged with various venture capital firms. Now, we are pleased to bring you SR-one, who will be engaged with select members and offer insight and discuss potential collaborations.
How can you participate?
SR-one is interested in meeting with innovation-oriented companies working towards discovering new drugs, with novel modalities and novel mechanisms of action.
All therapeutic areas are of interest - must have unmet medical needs in the area. Investment stage span from seed stage through Series stages (A/B/C/etc).
If you would like to submit your company for review for the one-on-one meetings, please send a one page non-confidential executive summary to Oscar Rodarte at email@example.com.
Important Event Details:
Event Date: Wednesday, May 3rd
Deadline to submit an application is Wednesday, April 19th
* Source: MoneyTree™ Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA); based on data provided by Thomson Reuters